MacDougall Ann L. 4
4 · OPIANT PHARMACEUTICALS, INC. · Filed May 13, 2021
Insider Transaction Report
Form 4
MacDougall Ann L.
Director
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2021-05-13$10.00/sh−341$3,410→ 0 totalExercise: $10.00Exp: 2021-05-16→ Common Stock (341 underlying) - Exercise/Conversion
Common Stock
2021-05-13$10.00/sh+341$3,410→ 21,179 total
Footnotes (1)
- [F1]On May 17, 2016, the reporting person was granted an option to purchase 35,000 shares of Common Stock. The options vest as follows: (i) 11,667 share upon the up listing of the Issuer to The NASDAQ Stock Market (which occurred on August 29, 2017); (ii) 11,667 shares upon the cumulative funding of the Issuer in excess of $5,000,000 by institutional investors, commencing May 5, 2016 (which performance criteria was met on December 13, 2016); and (iii) 11,666 shares upon the first submission of a New Drug Application ("NDA") to the FDA for one of Issuer's products by either the Issuer or an Issuer licensee.